Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling

Yoshihiro Ono, Tetsu Hayashida, Ayano Konagai, Hiroshi Okazaki, Kazuhiro Miyao, Shigeyuki Kawachi, Minoru Tanabe, Masahiro Shinoda, Hiromitsu Jinno, Hirotoshi Hasegawa, Masaki Kitajima, Yuukou Kitagawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) is involved in the regulation of cell proliferation, differentiation, and apoptosis and is associated with epithelial-mesenchymal transition (EMT). Inhibition of the TGF-β pathway is an attractive strategy for the treatment of cancer. We recently screened for novel TGF-β inhibitors among commercially available drugs and identified protein-bound polysaccharide (PSK) as a strong inhibitor of the TGF-β-induced reporter activity of 3TP-lux, a TGF-β1-responsive luciferase reporter. Protein-bound polysaccharide is used as a non-specific immunostimulant for the treatment of gastric and colorectal cancers in Japan. The anticancer activity of this agent may involve direct regulation of growth factor production and enzyme activity in tumors in addition to its immunomodulatory effect. Although several clinical studies have shown the beneficial therapeutic effects of PSK on various types of tumors, its mechanism of action is not clear. In the present study, Western blot analysis showed that PSK suppressed the phosphorylation and nuclear localization of the Smad2 protein, thereby suggesting that PSK inhibits the Smad and MAPK pathways. Quantitative PCR analysis showed that PSK decreased the expression of several TGF-β pathway target genes. E-cadherin and vimentin immunohistochemistry showed that PSK suppressed TGF-β1-induced EMT, and FACS analysis showed that PSK inhibited the EMT-mediated generation of CD44 +/CD24 - cells. These data provide new insights into the mechanisms mediating the TGF-β-inhibiting activity of PSK and suggest that PSK can effectively treat diseases associated with TGF-β signaling.

Original languageEnglish
Pages (from-to)317-324
Number of pages8
JournalCancer Science
Volume103
Issue number2
DOIs
Publication statusPublished - 2012 Feb

Fingerprint

Transforming Growth Factors
Polysaccharides
Proteins
Epithelial-Mesenchymal Transition
Smad2 Protein
krestin
Immunologic Adjuvants
Neoplasms
Growth Inhibitors
Therapeutic Uses
Vimentin
Cadherins
Luciferases
Antineoplastic Agents
Stomach Neoplasms
Cell Differentiation
Colorectal Neoplasms
Intercellular Signaling Peptides and Proteins
Japan
Western Blotting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. / Ono, Yoshihiro; Hayashida, Tetsu; Konagai, Ayano; Okazaki, Hiroshi; Miyao, Kazuhiro; Kawachi, Shigeyuki; Tanabe, Minoru; Shinoda, Masahiro; Jinno, Hiromitsu; Hasegawa, Hirotoshi; Kitajima, Masaki; Kitagawa, Yuukou.

In: Cancer Science, Vol. 103, No. 2, 02.2012, p. 317-324.

Research output: Contribution to journalArticle

Ono, Yoshihiro ; Hayashida, Tetsu ; Konagai, Ayano ; Okazaki, Hiroshi ; Miyao, Kazuhiro ; Kawachi, Shigeyuki ; Tanabe, Minoru ; Shinoda, Masahiro ; Jinno, Hiromitsu ; Hasegawa, Hirotoshi ; Kitajima, Masaki ; Kitagawa, Yuukou. / Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. In: Cancer Science. 2012 ; Vol. 103, No. 2. pp. 317-324.
@article{58f0c3dceeb848668c9246d170039903,
title = "Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling",
abstract = "Transforming growth factor-β (TGF-β) is involved in the regulation of cell proliferation, differentiation, and apoptosis and is associated with epithelial-mesenchymal transition (EMT). Inhibition of the TGF-β pathway is an attractive strategy for the treatment of cancer. We recently screened for novel TGF-β inhibitors among commercially available drugs and identified protein-bound polysaccharide (PSK) as a strong inhibitor of the TGF-β-induced reporter activity of 3TP-lux, a TGF-β1-responsive luciferase reporter. Protein-bound polysaccharide is used as a non-specific immunostimulant for the treatment of gastric and colorectal cancers in Japan. The anticancer activity of this agent may involve direct regulation of growth factor production and enzyme activity in tumors in addition to its immunomodulatory effect. Although several clinical studies have shown the beneficial therapeutic effects of PSK on various types of tumors, its mechanism of action is not clear. In the present study, Western blot analysis showed that PSK suppressed the phosphorylation and nuclear localization of the Smad2 protein, thereby suggesting that PSK inhibits the Smad and MAPK pathways. Quantitative PCR analysis showed that PSK decreased the expression of several TGF-β pathway target genes. E-cadherin and vimentin immunohistochemistry showed that PSK suppressed TGF-β1-induced EMT, and FACS analysis showed that PSK inhibited the EMT-mediated generation of CD44 +/CD24 - cells. These data provide new insights into the mechanisms mediating the TGF-β-inhibiting activity of PSK and suggest that PSK can effectively treat diseases associated with TGF-β signaling.",
author = "Yoshihiro Ono and Tetsu Hayashida and Ayano Konagai and Hiroshi Okazaki and Kazuhiro Miyao and Shigeyuki Kawachi and Minoru Tanabe and Masahiro Shinoda and Hiromitsu Jinno and Hirotoshi Hasegawa and Masaki Kitajima and Yuukou Kitagawa",
year = "2012",
month = "2",
doi = "10.1111/j.1349-7006.2011.02133.x",
language = "English",
volume = "103",
pages = "317--324",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling

AU - Ono, Yoshihiro

AU - Hayashida, Tetsu

AU - Konagai, Ayano

AU - Okazaki, Hiroshi

AU - Miyao, Kazuhiro

AU - Kawachi, Shigeyuki

AU - Tanabe, Minoru

AU - Shinoda, Masahiro

AU - Jinno, Hiromitsu

AU - Hasegawa, Hirotoshi

AU - Kitajima, Masaki

AU - Kitagawa, Yuukou

PY - 2012/2

Y1 - 2012/2

N2 - Transforming growth factor-β (TGF-β) is involved in the regulation of cell proliferation, differentiation, and apoptosis and is associated with epithelial-mesenchymal transition (EMT). Inhibition of the TGF-β pathway is an attractive strategy for the treatment of cancer. We recently screened for novel TGF-β inhibitors among commercially available drugs and identified protein-bound polysaccharide (PSK) as a strong inhibitor of the TGF-β-induced reporter activity of 3TP-lux, a TGF-β1-responsive luciferase reporter. Protein-bound polysaccharide is used as a non-specific immunostimulant for the treatment of gastric and colorectal cancers in Japan. The anticancer activity of this agent may involve direct regulation of growth factor production and enzyme activity in tumors in addition to its immunomodulatory effect. Although several clinical studies have shown the beneficial therapeutic effects of PSK on various types of tumors, its mechanism of action is not clear. In the present study, Western blot analysis showed that PSK suppressed the phosphorylation and nuclear localization of the Smad2 protein, thereby suggesting that PSK inhibits the Smad and MAPK pathways. Quantitative PCR analysis showed that PSK decreased the expression of several TGF-β pathway target genes. E-cadherin and vimentin immunohistochemistry showed that PSK suppressed TGF-β1-induced EMT, and FACS analysis showed that PSK inhibited the EMT-mediated generation of CD44 +/CD24 - cells. These data provide new insights into the mechanisms mediating the TGF-β-inhibiting activity of PSK and suggest that PSK can effectively treat diseases associated with TGF-β signaling.

AB - Transforming growth factor-β (TGF-β) is involved in the regulation of cell proliferation, differentiation, and apoptosis and is associated with epithelial-mesenchymal transition (EMT). Inhibition of the TGF-β pathway is an attractive strategy for the treatment of cancer. We recently screened for novel TGF-β inhibitors among commercially available drugs and identified protein-bound polysaccharide (PSK) as a strong inhibitor of the TGF-β-induced reporter activity of 3TP-lux, a TGF-β1-responsive luciferase reporter. Protein-bound polysaccharide is used as a non-specific immunostimulant for the treatment of gastric and colorectal cancers in Japan. The anticancer activity of this agent may involve direct regulation of growth factor production and enzyme activity in tumors in addition to its immunomodulatory effect. Although several clinical studies have shown the beneficial therapeutic effects of PSK on various types of tumors, its mechanism of action is not clear. In the present study, Western blot analysis showed that PSK suppressed the phosphorylation and nuclear localization of the Smad2 protein, thereby suggesting that PSK inhibits the Smad and MAPK pathways. Quantitative PCR analysis showed that PSK decreased the expression of several TGF-β pathway target genes. E-cadherin and vimentin immunohistochemistry showed that PSK suppressed TGF-β1-induced EMT, and FACS analysis showed that PSK inhibited the EMT-mediated generation of CD44 +/CD24 - cells. These data provide new insights into the mechanisms mediating the TGF-β-inhibiting activity of PSK and suggest that PSK can effectively treat diseases associated with TGF-β signaling.

UR - http://www.scopus.com/inward/record.url?scp=84856500296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856500296&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2011.02133.x

DO - 10.1111/j.1349-7006.2011.02133.x

M3 - Article

VL - 103

SP - 317

EP - 324

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -